scholarly journals Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study

2011 ◽  
Vol 106 (1) ◽  
pp. 233-239 ◽  
Author(s):  
M C Bradley ◽  
L J Murray ◽  
M M Cantwell ◽  
C M Hughes
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Case Control Study ◽  
Case Control ◽  
Receptor Antagonists ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

scholarly journals A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers

2006 ◽  
Vol 66 (20) ◽  
pp. 10213-10219 ◽  
Author(s):  
Rachael Z. Stolzenberg-Solomon ◽  
Reinhold Vieth ◽  
Azar Azad ◽  
Pirjo Pietinen ◽  
Philip R. Taylor ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vitamin D ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Vitamin D Status ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

Statins and pancreatic cancer risk: a nested case–control study

2010 ◽  
Vol 21 (12) ◽  
pp. 2093-2100 ◽  
Author(s):  
Marie C. Bradley ◽  
Carmel M. Hughes ◽  
Marie M. Cantwell ◽  
Liam J. Murray
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

scholarly journals Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study

2010 ◽  
Vol 102 (9) ◽  
pp. 1415-1421 ◽  
Author(s):  
M C Bradley ◽  
C M Hughes ◽  
M M Cantwell ◽  
G Napolitano ◽  
L J Murray
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Nested Case Control ◽  
Control Study

scholarly journals DNA methylation derived immune cell profiles, CpG markers of inflammation, and pancreatic cancer risk

2020 ◽  
Author(s):  
Dominique S. Michaud ◽  
Mengyuan Ruan ◽  
Devin C. Koestler ◽  
Lola Alonso ◽  
Esther Molina-Montes ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dna Methylation ◽  
Cancer Risk ◽  
Case Control Study ◽  
Immune Cell ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Markers Of Inflammation ◽  
Nested Case Control ◽  
Control Study

AbstractPancreatic cancer is projected to become the second most common cause of cancer death over the next 5 years. Since inflammation is thought to be a common trajectory for disease initiation, we sought to prospectively characterize immune profiles using DNA methylation markers to examine whether they play a key role in pancreatic cancer risk. In a nested case-control study pooling three U.S. prospective cohort studies, DNA methylation was measured in prediagnostic leukocytes of incident pancreatic cancer cases and matched controls using the Illumina MethylationEPIC array. Differentially methylated regions were used to predict immune cell types and CpGs previously associated with blood inflammatory markers were selected for the analysis. DNA methylation data from a retrospective case-control study conducted in Spain (PanGenEU) was used for independent replication of results. Immune cell proportions and ratio of cell proportions were not associated with pancreatic cancer risk in the nested case-control study. Methylation extent of CpGs residing in or near gene MNDA was significantly associated with pancreatic cancer risk in the nested case-control study and replicated in PanGenEU. In the nested case-control study, the associations were present 10 or more years prior to cancer diagnosis. Methylation of a promoter CpG of gene PIM-1 was associated with pancreatic cancer survival in both studies. We identified several CpGs that may play a role in pancreatic carcinogenesis using a targeted approach for the selection of inflammation-based CpGs in two large, independent studies conducted in different countries with distinct study designs.

Assessing the effects of beta‐blockers on pancreatic cancer risk: A nested case‐control study

2020 ◽  
Vol 29 (5) ◽  
pp. 599-604
Author(s):  
Akram Saad ◽  
Jeffrey Goldstein ◽  
Ofer Margalit ◽  
Einat Shacham‐Shmueli ◽  
Yaacov R. Lawrence ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Beta Blockers ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

scholarly journals Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case–control study

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e041543
Author(s):  
Keiko Ikuta ◽  
Shunsaku Nakagawa ◽  
Kenji Momo ◽  
Atsushi Yonezawa ◽  
Kotaro Itohara ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Case Control Study ◽  
Kidney Injury ◽  
Case Control ◽  
Renal Diseases ◽  
Increased Risk ◽  
Nested Case Control ◽  
Control Study

ObjectivesThis study aimed to assess whether the combined use of proton pump inhibitors (PPIs) with non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics (penicillins, macrolides, cephalosporins or fluoroquinolones) was associated with an increased risk of acute kidney injury (AKI).DesignA nested case–control study.SettingA health insurance claims database constructed by the Japan Medical Data Center.ParticipantsPatients were eligible if they were prescribed a PPI, NSAID and antibiotic at least once between January 2005 and June 2017. The patients who were new PPI users and did not have any history of renal diseases before cohort entry were included (n=219 082). The mean age was 45 and 44% were women.InterventionsCurrent use of PPIs, NSAIDs, or antibiotics.Primary outcome measuresAcute kidney injury.ResultsDuring a mean follow-up of 2.4 (SD, 1.7) years, 317 cases of AKI were identified (incidence rate of 6.1/10 000 person-years). The current use of PPIs was associated with a higher risk of AKI compared with past PPI use (unadjusted OR, 4.09; 95% CI, 3.09 to 5.44). The unadjusted ORs of AKI for the current use of PPIs with NSAIDs, cephalosporins and fluoroquinolones, compared with the current use of PPIs alone, were 3.92 (95% CI, 2.40 to 6.52), 2.57 (1.43 to 4.62) and 3.08 (1.50 to 6.38), respectively. The effects of concurrent use of PPIs with NSAIDs, cephalosporins or fluoroquinolones remain significant in the adjusted model. The analyses on absolute risk of AKI confirmed the results from the nested case–control study.ConclusionsConcomitant use of NSAIDs with PPIs significantly increased the risk for AKI. Moreover, the results suggested that concomitant use of cephalosporins or fluoroquinolones with PPIs was associated with increased risk of incident AKI.

scholarly journals Association between Alcohol Consumption and Pancreatic Cancer Risk: A Case-Control Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0124489 ◽  
Author(s):  
Farah Rahman ◽  
Michelle Cotterchio ◽  
Sean P. Cleary ◽  
Steven Gallinger
Keyword(s):  
Pancreatic Cancer ◽  
Alcohol Consumption ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document